A clinical pharmacy specialist discusses what’s needed to get the REMS program set up and touches on reimbursement considerations for the administration of belantamab mafodotin in patients with multiple myeloma.
Kathryn Maples, PharmD, BCOP
Advertisement
Articles by Kathryn Maples, PharmD, BCOP
A clinical pharmacy specialist details her experience with the REMS program for administration of belantamab mafodotin in patients with multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
3
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
4
TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)
5